Methods and compositions for wound healing
US-2024139237-A1 · May 2, 2024 · US
Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity
US9168250B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9168250-B2 |
| Application number | US-201313855806-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 3, 2013 |
| Priority date | Oct 31, 2002 |
| Publication date | Oct 27, 2015 |
| Grant date | Oct 27, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to the use of a ligand of the 5-HT 4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT 4 receptor or of a functionally equivalent receptor for a drug for treating and/or preventing a pathology associated with an obsessional behavior such as anorexia, bulimia and the addiction to drugs of abuse or obesity. The invention also relates to a method for identifying a compound that is biologically active in the treatment and/or the prevention of a pathology associated with an obsessional conduct or obesity including: a) placing the 5-HT 4 receptor or a functionally equivalent receptor in contact with this biologically active compound, and b) the determination of whether this biologically active compound is capable of modulating the basal activity of the 5-HT 4 receptor or of a functionally equivalent receptor.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating a pathology associated with an obsessional behavior of a mammal in need thereof, wherein the pathology is anorexia, the method comprising administering a therapeutically effective amount of an antagonist of a 5-HT 4 receptor, an inverse agonist of a 5-HT 4 receptor, a pharmaceutically acceptable salt of the antagonist, or a pharmaceutically acceptable salt of the inverse agonist to the mammal to treat the mammal.…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
- A61K31/445Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9168250B2 cover?
- This invention relates to the use of a ligand of the 5-HT 4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT 4 receptor or of a functionally equivalent receptor for a drug for treating and/or preventing a pathology associated with an obsessional behavior such as anorexia, bulimia and the addiction to drugs of abuse or obesity. The invent…
- Who is the assignee on this patent?
- Ct Nat De La Rech Scientifique—Cnrs, Centre Nat Rech Scient
- What technology area does this patent fall under?
- Primary CPC classification A61K31/445. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).